KMT

KMT Hepatech is a specialized biotechnology company and contract research organization (CRO) focused on humanized liver models for preclinical drug development. Based in Edmonton, Canada, the company is renowned for its proprietary KMT Mouse, a chimeric model in which the mouse liver is repopulated with human hepatocytes. This platform allows researchers to study human-specific liver infections, drug metabolism, and toxicology in an in vivo environment that closely mimics human physiology. KMT Hepatech provides essential services for evaluating therapeutic candidates against Hepatitis B, Hepatitis C, and Malaria, as well as conducting ADME and safety assessments. In 2017, the company was acquired by PhoenixBio, a global leader in humanized liver technology, to enhance its service capabilities and market reach. The company's technology remains a vital tool for biopharmaceutical firms seeking to bridge the gap between in vitro studies and clinical trials for liver-targeted therapies.